A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
NCT07735546
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma in Relapse
Multiple Myeloma (MM)
Interventions
GENETIC:
UB-VV500
DRUG:
Rapamycin (sirolimus)
Sponsor
Umoja Biopharma